Brokerages Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $58.83

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received a consensus rating of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $60.60.

A number of equities research analysts have recently weighed in on the company. Citigroup lifted their target price on Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. BTIG Research lifted their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. decreased their target price on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Finally, Stephens reiterated an “overweight” rating and issued a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th.

Establishment Labs Trading Down 4.6 %

Shares of Establishment Labs stock opened at $37.51 on Friday. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91. The business has a fifty day simple moving average of $43.32 and a two-hundred day simple moving average of $45.75. Establishment Labs has a 1 year low of $21.25 and a 1 year high of $60.12. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -14.36 and a beta of 1.20.

Institutional Trading of Establishment Labs

A number of institutional investors have recently made changes to their positions in ESTA. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Establishment Labs by 1.8% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 35,236 shares of the company’s stock worth $1,525,000 after acquiring an additional 632 shares during the period. Hood River Capital Management LLC bought a new position in Establishment Labs during the second quarter valued at approximately $43,000. Verition Fund Management LLC grew its holdings in shares of Establishment Labs by 22.8% in the third quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after acquiring an additional 1,746 shares during the period. California State Teachers Retirement System grew its stake in shares of Establishment Labs by 14.5% during the 1st quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock valued at $870,000 after purchasing an additional 2,167 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Establishment Labs in the third quarter worth approximately $127,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.